Core Insights - The article highlights that Innovent Biologics has achieved a significant milestone with its GCG/GLP-1 dual receptor agonist, Ma Shidu Peptide, demonstrating superior efficacy in blood glucose control and weight management compared to Semaglutide in the DREAMS-3 Phase III clinical trial [1][3][4] Group 1: Clinical Trial Results - The DREAMS-3 trial is the first head-to-head Phase III clinical study comparing a GCG/GLP-1 dual receptor agonist with Semaglutide in diabetes treatment, marking a breakthrough for domestic innovative drugs [1][3] - After 32 weeks of treatment, 48% of Ma Shidu Peptide patients achieved both blood glucose targets (HbA1c < 7.0%) and weight loss of ≥10%, significantly higher than the 21% in the Semaglutide group [3][4] - Ma Shidu Peptide showed an average blood glucose reduction of 2.03% compared to 1.84% for Semaglutide, and an average weight loss of 10.29% versus 6.00% [3][4] Group 2: Safety and Tolerability - The overall tolerability of Ma Shidu Peptide is good, with a low discontinuation rate due to adverse events and no new safety signals reported [4] - Common adverse events were mild to moderate gastrointestinal reactions, with a low incidence of hypoglycemia comparable to Semaglutide, and no reports of severe hypoglycemia [4] Group 3: Market Potential and Innovation - The GLP-1 drug market is projected to exceed $100 billion by 2030, driven by strong demand for effective and safe treatments for obesity and metabolic disorders [6] - Ma Shidu Peptide is the first and only GCG/GLP-1 dual receptor agonist approved for both weight management and type 2 diabetes treatment, positioning it as a competitive player in the market [6][8] - The innovative design of the injection pen, featuring a hidden needle and single-use format, enhances patient convenience and compliance, which is crucial for long-term treatment adherence [6][8]
信达生物公布玛仕度肽最新数据，展现降糖减重综合疗效优势